Pentoxifylline anaghị edozi microalbuminuria n'ime ndị ọrịa nwere ọrịa mellitus

Ọrịa na-adịghị ala ala nke ọrịa shuga mellitus na-eduga n'ịbelata oge na ogo ndụ ndị mmadụ na ọrịa a. Compkwụ ụgwọ maka ọrịa shuga siri ike iji nweta ma ọ ga - ekwe omume oge niile iji gbochie mmepe na mmepe nke nsogbu. N'iburu n'uche nje a na-ahụkarị maka nsogbu nke ọrịa shuga mellitus, ọ bụ ihe amamihe dị na ya ị systemụ ọgwụ systemic, nke gụnyere ọgwụ pentoxifylline na-abụghị nke a na-ahọrọ, nke na-enye nsonaazụ nke vasodilation na-adịghị ike, onye na-ahụ maka antiplatelet na angioprotector. A na-egosiputa nyocha nke ojiji nke pentoxifylline n'ọtụtụ nsogbu na-adịghị ala ala nke ọrịa shuga mellitus.

Ọrịa na-adịghị ala ala nke ọrịa shuga mellitus: na-elekwasị anya na pentoxifylline

Ọrịa shuga na-adị ala ala na-ebute site na mbelata ogologo ndụ na ịdị mma nke ndị nwere ọrịa a. Nkwụghachi ụgwọ ndị ọrịa shuga siri ike iji nweta ma ọ naghị ekwe ka igbochi mmepe na mmepe ha. N'iburu n'uche nsogbu nke pathogenesis nke ọrịa shuga, iji nkwadebe nke usoro usoro nke ọ bụghị na-ahọta ihe mgbochi nke phosphodiesterase pentoxifylline na-ejikọta mmetụta nke vasodilator na-adịghị ike, onye na-ahụ maka antiplatelet na angioprotectora. Nyocha nke arụmọrụ nke pentoxifylline n'ọtụtụ nsogbu na-adịghị ala ala nke ọrịa shuga ọkọnọ.

Ederede nke akwụkwọ sayensị na isi okwu "Ọrịa shuga na-arịa ọrịa shuga: ilekwasị anya na pentoxifylline"

AKW ARKWỌ NSỌ NA Nyocha NA

Ọrịa na-adịghị ala ala nke ọrịa shuga: a na-elekwasị anya na pentoxifylline

dọkịta nke sayensị sayensị, prọfesọ nke 1st ngalaba nke ọrịa nke ime nke Belarusian State Medical University

MokhortT. Mahadum Belarusian State Medical University, Minsk Ọrịa na-adịghị ala ala nke ọrịa shuga mellitus:

gbado anya na pentoxifylline

Nchikota Ọrịa na-adịghị ala ala nke ọrịa shuga mellitus na-eduga n'ịbelata oge na ogo ndụ ndị mmadụ na ọrịa a. Compkwụ ụgwọ maka ọrịa shuga siri ike iji nweta ma ọ ga - ekwe omume oge niile iji gbochie mmepe na mmepe nke nsogbu. N'iburu n'uche nje a na-ahụkarị maka nsogbu nke ọrịa shuga mellitus, ọ bụ ihe amamihe dị na ya ị systemụ ọgwụ systemic, nke gụnyere ọgwụ phosphodiesterase na-abụghị nhọrọ - pentoxifylline, nke na-enye nsonaazụ nke vasodilation na-adịghị ike, onye na-ahụ maka antiplatelet na angioprotector. A na-egosiputa nyocha nke ojiji nke pentoxifylline n'ọtụtụ nsogbu na-adịghị ala ala nke ọrịa shuga mellitus.

Keywords: ọrịa mellitus, ọrịa na-adịghị ala ala, pentoxifylline, retinopathy na-arịa ọrịa shuga, nephropathy na-arịa ọrịa shuga, ọrụ ọgụgụ isi, ọrịa imeju na-adịghị egbu egbu, ọrịa obi.

Akụkọ gbasara ahụike. - 2015. - Nke 4. - S. 4-9.

Nchikota Ọrịa shuga na-adị ala ala na-ebute site na mbelata ogologo ndụ na ịdị mma nke ndị nwere ọrịa a. Nkwụghachi ụgwọ ndị ọrịa shuga siri ike iji nweta ma ọ naghị ekwe ka igbochi mmepe na mmepe ha. N'iburu n'uche nsogbu nke pathogenesis nke ọrịa shuga, iji nkwadebe nke usoro usoro nke ọ bụghị na-ahọta ihe mgbochi nke phosphodiesterase - pentoxifylline na-ejikọta mmetụta nke vasodilator na-adịghị ike, onye na-ahụ maka antiplatelet na angioprotectora. Nyocha nke arụmọrụ nke pentoxifylline n'ọtụtụ nsogbu na-adịghị ala ala nke ọrịa shuga ọkọnọ.

Isi okwu: mellitus ọrịa shuga, nsogbu na-adịghị ala ala, pentoxifylline, ọrịa mamma retinopathy diphicathy, ọrụ ọgụgụ isi, ọrịa na-adịghị egbu egbu nke mmanya, obi ike.

Meditsinskie novosti. - 2015. - N4. - P. 4-9.

Ọrịa, ma ọ bụ mbubreyo, nsogbu nke ọrịa shuga mellitus (DM) bụ ihe kpatara mbelata oge na ogo ndụ ndị mmadụ nwere ọrịa a. N’oge ọdịnala, ụdịdị dị iche iche nke ọrịa na-adịghị ala ala gụnyere microangiopathies (retinopathy, nephropathy), neuropathy na macroangiopathies (atherosclerosis of the coronary arteries with development of ọrịa coronary artery, cerebral and other peripheral arteries). N'afọ ndị na-adịbeghị anya, ekwuola ọtụtụ ugboro banyere ọrịa imeju na-egbu egbu na oke oke yana ụdị ọrịa shuga 2, nke na-enye anyị ohere ijikọ ọrịa a na nsogbu na-adịghị ala ala nke ọrịa shuga. Ọnụnọ nke nrụrụaka na dementia na-adọta uche, nke na-achọpụta mkpa ọ dị ịzụlite ụzọ maka ọgwụgwọ ha.

Ọtụtụ nnyocha achọpụtala ihe ndị dị ize ndụ maka mmepe nke nsogbu (hyperglycemia, ọbara mgbali elu, dyslipidemia) ma chọpụta ụzọ dị iche iche iji gbochie yana ịgwọ nsogbu ọrịa shuga na-adịghị ala ala. E gosipụtara nyocha nke ọmụmụ nke na-elele nsonaazụ nke nkwụghachi ụgwọ maka metabolism metabolism, normalization nke ọbara mgbali na profaịlụ lipid.

belata ihe ize ndụ nke ịmalite nsogbu n'oge, mana, ọ bụ ihe nwute, ọ bụghị mgbochi ha na ọgwụgwọ ha dum. N'ụzọ doro anya, ọdịdị ọdịdị nke pathogenesis nke ọrịa shuga na-ekpebi mkpa ọ dị maka usoro ndị ọzọ iji metụta ihe na-aga n'ihu nke angio- na neuropathies. Ruo ọtụtụ afọ, ejirila ya dị ka ọgwụ maka ọgwụgwọ na mgbochi nke ọrịa vaskụla na-arịa ọrịa shuga.

ihe mgbochi phosphodiesterase na-abụghị nhọrọ - pentoxifylline (PF), na-ejikọ nsonaazụ nke vasodilator na-adịghị ike, onye na-ahụ maka antiplatelet na angioprotector. A rụrụ PF na 1965 dịka ihe dị na ọtụtụ methylxanthines nwere akụrụngwa vasodilating. Mgbe nyochachara ọgwụgwọ na nyocha nke ụlọ ọgwụ dị na 1972, na ntinye nke Grigoleit na Werner, a malitere iji ọgwụ ahụ na-adakarị

Mbido ọrịa shuga

Isi Okwu Obu Mmetụta Ọrịa Shuga (Brownlee M.) Fonseca V.A. Ọrịa ọrịa shuga na-atụgharị uche na-eme nyocha ihe ọmụmụ nyocha 2006

t Collagen t Fibronectin

Iwu Imebi. Mwepu Nwepu nke Mgbakwunye ga-enwe mkpali. otutu mkpụrụ ndụ ihe nketa

ọbara igba angiogenesis nke vaskụla capillaries mmetụta

Nsonaazụ mbụ nke 1Я1logical nke pentoxifylline

Njirimara bụ isi Ihe omume ndị ọzọ

Ọbara na - agwọkwa ọbara Ọbara

Ọhụhụ ọbara na obara ọbara

Ike nrụrụ erythrocyte +

¿Na-ekesa plasma fibrinogen + +

Ike nrụrụ nke leukocytes + +

Hes Nchịkọta na nchịkọta nke leukocytes + + +

¿Zoro ezo nke ọgwụ na-egbu onwe ha site na mkpụrụ ndụ ọgbụgba + +

¿Ingmepụta ihe a na - akpọ FAT + +

¿Mmepụta nke TNF-a monocytes + +

Response Leukocyte nzaghachi na TNF-a +

Response Nzaghachi Leukocyte na IL-2 +

Activity Ọrụ na-egbu egbu +

Coagulation ọbara na fibrinolysis

Tissue plasminogen activates + +

Ahụ ọnya na ọnya anụ ahụ

¿Nzaghachi TNF-a fibroblasts +

IHE: FAT bụ ihe na - eme ka platelet pụta, + ọ bụ nsonaazụ dị mma, | - mụbaa, - belata.

na-eme ka emeziwanye usoro na microvasculature.

A na - ahụta usoro nke PF site na mmụba nke c-AMP na ATP yana mbelata nke oriri na - eme ka calcium na sel. N'ihi nke PF:

- na-abawanye ihe plasticful nke akpụkpọ ahụ nke sel ọbara ọbara ma belata ogo nrụrụ,

- na-ebelata mkpokọta nke sel ọbara-ọbara,

- nwere mmetụta vasodilating adịghị ike,

- na-ebelata viscosity ọbara (ịba ụba fibrinolysis na mbelata nke fibrinogen).

- na - ebelata platelet,

- na - ewepụ mmetụta mbibi nke neutrophils na endothelium.

Ngwongwo ndị edepụtara bụ ihe dị mkpa na-arịa ọrịa shuga, ebe ọ bụ na mmụba nke ọkwa hemoglobin nke glycated na hyperglycemia na-adịghị ala ala na-agbanwe ike nke mkpụrụ ndụ ọbara uhie ma na-abawanye njikwa na ibelata nrụrụ.

N'ihi usoro kemịkal ya, PF nwere ikike ịbawanye njikọta prostacyclin ma belata nguzobe nke thromboxane A2 na sel endothelial, gbochie njikọ tumor necrotic factor-a (TNF-a) na cytokines ndị ọzọ, gbanwee plasma fibrinogen ịta na ọrụ nke plasminogen activator inhibitor. igbochi phosphodiesterase, nke na-eduga na mkpokọta cAMP 17, 32, 35, 39 na platelet. Ihe ndị a niile na - egbochi nrabe nke platelet na mkpụrụ ndụ ọbara uhie, nke na - emetụta oke akụrụngwa nke Blood Properties.

Enyere mmetụta ndu nke PF na tebụl. Ihe karịrị afọ iri anọ nke ahụmịhe nke iji PF (n'ọmụmụ ihe niile ụdị PF - ejiri Trental mee ihe) na-egosi arụmọrụ ya n'ọrịa dị iche iche, mana, na-elekwasị anya na ọrịa shuga, anyị na-enyocha ohere nke iji PF maka nsogbu dịgasị iche iche na-adịghị ala ala.

Ọrịa ọgbụgba na-adịghị ala ala nke akwara dị ala (HOSANK) bụ ihe kpatara mmepe nke ischemic na ụdị dịgasị iche iche nke ịrịa ọrịa mamịrị. Obi abụọ adịghị ya na usoro ọgwụgwọ bụ isi sitere na mweghachi ọbara na-erugharị na akwara, i.e. ihe ndị a na - atụgharị uche na ọnụnọ nke ọnụnọ isi Usoro mgbochi na ọgwụgwọ gụnyere, na mgbakwunye na ndụmọdụ ndị a na-anabatakarị (kwụọ ụgwọ maka metabolism metabolism,

dyslipidemia, normalisation nke ọbara mgbali), ọzọ. Ọzọ aro:

- ụwe anwụrụ anwụrụ arụ, arụ ọrụ (n'ihu ọnụnọ nke oge nkeji iri anọ na ise ruo 60 ruo oge ihe mgbu ga-apụta na izu ike ugboro atọ n'izu),

- ihe mgbochi antiplatelet na antithrombotic - aspirin ma ọ bụ thienopyridines (ticlopidine ma ọ bụ clopidogrel) ma ọ bụ platelet glycoprotein IIb / IIIa inhibitors (abciximab, eptifibatide, tirofiban).

Iji kpochapụ ihe mgbaàmà nke ịkọwapụta ihe dị omimi, ihe nkedo quinolinone, Cilostazol, edighi edebanye aha na Republic of Belarus dị ka ọgwụ mbụ ịhọrọ. Cilostazol na-egbochi ụdị 3 phosphodiesterase ma na-abawanye ọdịnaya intracellular nke CAMP, na-echeghachite nchịkọta platelet, ngabiga nke aspirin, dipyridamole, ticlopidine na PF, na-egbochi nguzo nke artromromosiki na ịgbasa mkpụrụ ndụ akwara dị larịị, nwere vasodilator na hypo-lipid. Cilosta-zol bụ naanị ọgwụ nke belatara usoro nke restenoses mgbe etinyechara ya na stenti ọla (CREST).

Nyere enweghi ike iji cilostazol, ọgwụ ịhọrọ bụ PF, ojiji nke, dị ka nsonaazụ nke meta-nyocha nke ọmụmụ 23, gụnyere nlebara anya nke ndị ọrịa 2816, na-amụba oge na-adịghị egbu mgbu nke ije ije na ngụkọta oge nke ije ije na-agagharị agagharị (ogbo Fontaine 2). N'ime ihe ọmụmụ ndị a gụnyere, ụzọ ịga ije na-enweghị mgbu siri ike site na 33.8 ruo 73.9%. Na mgbakwunye, cilostazol yikarịrị ka PF na-akpata nsonaazụ (isi ọwụwa, nsogbu ọnya, afọ ọsịsa na palpitations). N’ihota ihe omuma di obere banyere cilostazol ma e jiri ya tụnyere PF, enwere obere onodu data banyere odi nma na nnabata nke ogwu ndia na oke ego nke usoro ọgwụgwọ ya na cilostazol, ekwesiri ibu PF na nmalite ogwu ahu, ekwenyeghi kwa cilostazol ka oburu PF enweghi ike.

Ebumnuche maka iji PF na HOZANK gụnyere ọrụ a nwapụtara egosipụtara mmekpa ahụ "oyi" na-adịghị ala ala, nke a na-egosipụta ọ bụghị naanị site na mmụba nke ọrụ akara ya, kamakwa site na njikwa ngwaahịa.

endothelium nke procoagulant anụ ahụ na-akpata, leukocyte adhesion, mgbochi nke endothelial nitric oxide synthesis, ịgbado ọrụ nke onye na - egbochi mkpụkọ plasminogen-1. Usoro ndị a na-enye aka na vasoconstriction ma na-abawanye viscosity ọbara na ohere dị ukwuu nke thrombosis. Ọzọkwa, PF, dị ka m kwuru n’elu, nwere ike belata mgbanwe na mkpụrụ ndụ ọbara uhie na-abawanye ikike ha na-agbakwunye na ọnọdụ nke hyperglycemia 30, 45.

N’uche ndị dọkịta, enwere echiche elele mgbe ochie nke na - ekwupụta “ohi n’ ọpụpụ ”, nke na - ebilite mgbe onye ọrịa nwere conceritant neuropathy ma na - enwe mmetụta vasodilating. A na-akọwapụta usoro ndị dị mkpa nke Pf site na mmetụta ọ bụghị na lumen arịa ahụ, kama na ịdị omimi nke ọbara, nke na-ekweghị ka mmepe nke "ohi syndrome".

Ọtụtụ nnyocha emebeghị ka igosipụta abamuru nke PF n'ịgwọ ọrịa neuropathy mamịrị. Agbanyeghị, enwere nkwalite mgbanwe n'ọbara ọbara na-egbu egbu na njedebe akwara, yana nkwalite na mgbaàmà akwara ozi na ndị ọrịa nwere ụdị 1 na ụdị ọrịa shuga 2 na ọrịa neuropathy mgbe ha jisịrị PF 10, 27. EReggap et al. na-egosi na enweghị mmetụta ọgwụgwọ ọgwụgwọ PF na neuropathy na-esonye na nyocha dị mkpirikpi, ebe ọ nwere ike were afọ atọ ruo anọ iji bulie ogo.

Ọrịa ụkwara ume ọkụ n'ụdị dị iche iche na-esokarị ọnya trophic - ihe ndị a bụ ngosipụta nke abụọ nke ọrịa vaskụla ụnyahụ (HoAznk na varicose veins) na neuropathy. Mmepe nke ọnya trophic sitere na mmezi nke apoptosis, oke nke nchebe, erughi ihe na uto, cytokines na-arịa ọrịa, wdg ọgwụgwọ nke trophic ọnya dị n'ọtụtụ na iche, dabere na ihe kpatara ya, gụnyere omume iji meziwanye ọkọnọ ọbara (ọgwụgwọ nke isi vaskụla nsogbu), antibacterial ọgwụ (ma ọ bụrụ na gosiri), ọgwụgwọ obodo na-eji reparative ike nke ọgwụ. N'inye ntinye aka nke anakpo akuko nke akwara ohu na akwara varicose na mmepe nke mkpocha akwara obi, ihe nke PF na-ebelata oke mmetuta ahu na aka ekpeputara, na –eme ka ogwu di ike n’ile ndi nwere oria akwara isi.

n'ọtụtụ ndị ọrịa. Yabụ, n’ịkpọ ìsì gbara okpukpu abụọ, nke a na-atụghị anya ya, nke na-aga n’ihu, n’ọmụmụ ihe mmadụ 80 na-enyocha onyonyo gbasara mkpụkọ nke ọnya, mgbakwunye nke pentoxifylline n’usoro ọkọchị na mmachi ọnya na-eme ka ọnụọgụ nke ọgwụgwọ nke ọnya afọ.

A na - amata ọrịa retinopathy nke ọrịa mamịrị site na mgbanwe na ọkpụrụkpụ nke akpụkpọ ahụ okpuru ala, mmepe nke endothelial dysfunction na proliferation, mmebi nke mkpụrụ ndụ ọbara uhie yana oke ikuku oxygen (hypoxia), nchịkọta platelet, mbelata ọnụ ọgụgụ nke pericytes ya na mmepe nke ọurụysụ, azụ na edema na hemorrhages. Usoro ọgwụgwọ retinopathy dị mgbagwoju anya, nke na-eyigharị mkpa lasco photocoagulation nke retina, gụnyere ijigide ụgwọ maka ọrịa shuga, ọbara mgbali nkịtị (ọgwụ ndị mbụ na-ahọrọ angiotensin-na-emegharị ndị na-enzyme inhibitors), ọgwụ na-egbusi ike na ndị na-egbochi antiplatelet (aspirin, nke anaghị eme ka ohere nke ọbara ọgbụgba, ticlopidine ma ọ bụ PF). Ọ bụrụ na enwere data na-emegiderịta banyere ịdị adị nke iji statins na retinopathy (n'ọmụmụ ihe HPS na simvastatin otu, mkpa maka lasco photocoagulation laser na-adịghị mkpa (site na 8%), na ASCOT-LLA mmụba nke thrombosis retinal enweghị ntụkwasị obi (+ 3%), e jikwa atorvastatin mee ihe na CARDS butere mgbada na mbido nke DR yana mkpa lasco photocoagulation 6, 7, 34. Achọpụtawo mgbochi na ọgwụgwọ nke fenofibrate na nyocha FIELD na ACCORD 14, 42.

Ruo ọtụtụ afọ, ejirila PF mee ihe n'ịgwọ ọrịa mamịrị retinopathy. Ndabere nke usoro a dabere na ịkwalite usoro ọbara na mbenata azụ hypoxia na ndị ọrụ afọ ofufo nwere ahụ ike, na ndị ọrịa nwere nkwarụ akwara azụ na mwepu ọhụhụ, na ọrịa mamịrị retinopathy 8, 13, 33.

E. Ferrari gosiputara oganihu na ogwugwu nke ọbara na oke mmụba n'ọbara na capillaries nke retina na ndị ọrịa na-enweta PF ma e jiri ya tụnyere ndị ọrịa nọ na placebo, yana ikike nke PF igbochi neovascularization nke vitreous retina na retinal hemorrhages, gụnyere ndị ọrịa nwere ọrịa mamịrị retinopathy. Ebuputara data banyere iwetulata ọrịa retinopathy na ụmụaka nwere ọrịa shuga nke 1. Meta-analysis Otú ọ dị

Nsonaazụ nyocha-meta nke ịdị irè nke pentoxifylline na nephropathy ọrịa mamịrị: nsonaazụ na proteinuria

Nsonaazụ nke pentoxifylline na proteinuria na ọrịa akụrụ ọrịa mamịrị: nyocha-meta /

McCormick B. B., Sydor A., ​​Akbari A., Fergusson D., Doucette S., Knoll G. // Am. J. Kidney Dis. - 2008 .-- Vol. 52 (3). - P. 454 - 463.

Ihe ndekọ data Cochrane nke ọmụmụ 97 na-egosi mkpa ọ dị maka ọmụmụ ihe na-ezughị ezu na ijiwepụta zuru oke iji gosipụta ịdị irè nke ọrịa retinopathy na ọrịa shuga.

Ọrịa mamịrị na-arịa ọrịa mamịrị. Ebumnuche maka iji PF na ọrịa nephropathy na-arịa ọrịa mamịrị:

- Ihe ọ na - eme n ’ụmụ irighiri mmiri na irighiri akwara,

- nsonaazụ na sel na - ekesa, nrịbama nke mbufụt - neutrophils, monocytes, lymphocytes

- nsonaazụ ya na ngosipụta nke mbufụt "oyi" - mgbochi nke cytokines na-arụ ọrụ,

- mgbochi nke cumulation nke matrix extracellular.

E gosipụtara mmetụta bara uru nke PF na akụrụngwa hemorheological nke ọbara n'oge mmepe nke ọrịa mamịrị nephropathy site na mbelata ogo proteinuria n'ụdị ọrịa shuga 1 na nke 2, n'agbanyeghị metabolic akara na steeti ọrụ akụrụ 10, 12, 37, 38. A hụkwara mmetụta a na ndị ọrịa nwere ọrịa shuga na ọbara mgbali elu. onye natara PF dika monotherapy ma obu ihe jikoro ya na angiotensin-na-agbanwe enzyme inhibitors 23, 37. O di nkpa iburu n'uche na n’oge nyocha nke meta PF na proteinuria, uto hypoproteinuric ya siri ike.

E gosipụtara na PF na-enye ọ bụghị naanị mbelata protein urinary, ma na-agbadata ọkwa nke TNF-a na plasma ọbara, ọkwa nke ndị otu nephropathy mụbara nke ukwuu. PF nwere ike igbochi mwepu nke acetyl-p-glucosaminidase (akara nke akwara renal tubular) na mmamịrị, na-egosi mmetụta bara uru

Mmetụta doro anya ọ bụghị naanị na ngosipụta nke ọnya ụwa, kamakwa na mmebi akụrụ tubulo-interstitial na ndị ọrịa nwere ụdị shuga 2 21-23.

E hibere ya na TNF-a na ndị ọzọ pro-inflammatory cytokines na-arụ ọrụ dị mkpa na mmepe nke ọrịa mamịrị nephropathy 19, 20, 26. TNF-a bụ cytokine profunmatical profunctional nke nwere mkpụrụ ndụ macrophages, nke kachasị adipose anụ ahụ, yana mmetụta akpaaka na paracrine. ịbụ onye ogbugbo nke nguzogide insulin na akara nke mbufụt na-enweghị mgbochi, nke ọrụ ya na pathogenesis nke ọrịa nephropathy bụ ihe mgbochi, a na-egbochi PF, nke na -eme ka arụ ọrụ ọgwụgwọ ya.

N'ime otu etiti, atụmanya, na-eleghara anya, nke na-achịkwa PREDIAN n'ime ndị ọrịa 169 nwere ọrịa shuga 2 na ọrịa mamịrị (CKD st. 3-4), egosiri na mgbakwunye nke PF na angiotensin-na-agbanwe enzyme inhibitors na-abawanye mmetụta dị mma a na-enweta (mbelata proteinuria, serum creatinine, nchebe GFR, mbelata nke cytokines pro-mkpali TNF-a, interleukin-6 na 10).

Ya mere, agbanyeghi na anaghị etinye PF na ntinye aka ugbu a maka ọgwụgwọ ọrịa nephropathy, ọmụmụ ndị na-adịbeghị anya na-enye anyị ohere iwere ya dị ka ọgwụ na-ekwe nkwa maka ịgụnye na usoro ọgwụgwọ nke ọrịa a.

Mmetụta uche. N'agbanyeghị eziokwu ahụ bụ na a maara amara na mbelata nke ndị ọrịa na-arịa ọrịa shuga kemgbe 1922, mgbe W.R. Miles na H.F Root kọrọ banyere njikọ nke ọrịa a na ọrịa shuga, ekwenyela na eziokwu a n'ọtụtụ

ihe omumu, na “usoro” nke nsogbu na-adighi ala n’azu oria shuga, etinyeghi usoro a. Na agbanyeghị, inwe mkpachapu anya na ọrịa shuga nwere ọdịdị dị iche (akụkụ akwara, gụnyere ihe ọghọm nke ọrịa strok na nkwarụ ọnya ọgbụgba, amyloid deposition, glycemic fluctuations with activation of protein glycation and neuroglucopenia, wdg) ma edekọtara ndị mmadụ nwere ọrịa shuga ruo 25%. Ihe ọghọm nke dementia na ọrịa shuga dị elu karịa okpukpu 1.6 karịa karịa ọnụọgụ mmadụ niile, ihe ọghọm nke ọrịa akwara ji okpukpu oge 2.0-2.6 dị elu, ihe ọghọm nke ọrịa Alzheimer nwere okpukpu 1.5 karịa, n'agbanyeghị afọ ole onye malitere ọrịa shuga.

Ojiji nke PF na-akpata mmụba dị ukwuu na ngụkọta ọbara nke ụbụrụ, ọwa ọbara n'ime mpaghara nke ischemia cerebral adịghị eduga na ihe omume nke izu ohi intracerebral. Mmụta emere emere n'ime iri afọ ndị na-adịbeghị anya kpughere ihe ọhụrụ nke ọgwụ ahụ na-agbasawanye ohere nke iji ya na-adakarị n'ụdị dị iche iche nke ụbụrụ ischemia, nke na -emekarị usoro ọgwụgwọ na-ejikọ ọnụ ya na okwu "diski diskiculatory" (DE) na enweghị ihe akaebe nke ọdịda ọgụgụ isi. E gosiputara na nhọpụta nke PF na-abawanye na nkezi site na 20% mgbasa ụbụrụ mpaghara na nke izugbe na ndị ọrịa nwere ọrịa ụbụrụ na-adịghị ala ala.

Yabụ, na ntụle nke ọnwụnwa nlere anya 10 nke nyocha iji nyochaa arụmọrụ nke PF, achọpụtara mbelata mmụba nke ụkọ ọgbụgba, yana mbelata nke ihe ọghọm nke ịmalite ime ụbụrụ ụbụrụ ugboro ugboro.

Nnyocha usoro dabere na nsonaazụ nyocha nke ihe 20-nke yikarịrị, nke a na-ahazi, ọmụmụ ihe na-achịkwa anya, nwere ụzọ nyocha abụọ, iji nyochaa ịdị irè nke ọgwụ ahụ na ọgwụgwọ ndị ọrịa nwere nkwarụ akwara. E guzobere nsonaazụ dị mma nke PF (1200 mg / ụbọchị) na ndị ọrịa nwere akwara ọrịa vaskụla, nke amata n’ọkwa n’ike arụ ọrụ. Ọzọkwa, ịdị ogo na ịdị mkpa nke ọdịiche mụbara site na iji usoro ndị ọzọ siri ike maka nchọpụta nke akwara ike ọgwụgwụ.

Nnyocha dịgasị iche iche ekwenyela na ike nke iji PF mgbe ọ dị mkpa ka ọ metụta ụkọ nghọta: nkwụsị nke oganihu nke ọgụgụ isi.

nsogbu, ncheta ka mma, nlebara anya, ọkachasị ndị agadi 25, 29.

Ihe omuma banyere ikike nke PF iji belata onu ogugu nke mmetuta nke imerime mmadu bu ihe mmasi si ele anya nke iji ogwu eme ihe maka mgbochi nke ihe ngosi akwara nke oria achogho. E duzila ọmụmụ banyere ohere mmadụ nwere ike isi egbochi mmadụ igbu onwe ya.

Ike nke PFs gosipụtara iji gbochie mkpụrụ ndụ mononuclear sel, neutrophils na T-lymphocytes, gbochie njikọta cytokines pro-inflammatory nwere ike inye mmetụta nchebe ọzọ na mmepe nke ischemia ụbụrụ na mbelata nke ọgụgụ isi. O di nwute, enweghi ike ichota ihe omimi banyere nsogbu a emere na cohorts nke ndi oria di oria n’azu oria, mana usoro omumu ihe omumu banyere mmepe nke mmuta na egosi na ojiji nke PF ga enwe ezigbo nti na ikike nke ndi oria a.

Ọrịa imeju na-egbu egbu anaghị egbu egbu (NAFLD). Ekwuputara na n’ime ndi ọrịa nwere oke BMI nke 10-40% na nguzogide insulin, enwere ohere nke NAFLD. A na - ejikọkarị oke ibu na 95-100% na mmepe nke ịba ọcha n'anya yana na 20-47% nke steatohepatitis. Ọrịa shuga 2dị nke abụọ jikọtara ya na NAFLD na 75% nke ikpe. Njikọ nke ọrịa shuga na NAFLD nwere mmetụta na-adịghị mma na usoro ọrịa ndị a. Na NAFLD na ọrịa shuga, ugboro ugboro nke akwara ọbara, ọrịa ụbụrụ na akụkụ akwara na-abawanye, nke na-eduga n'ịbawanye n'ihe ize ndụ obi ma na-enye gị ohere igosipụta ọnụnọ nke NAFLD dị ka ihe ize ndụ maka ọrịa obi na ụdị ọrịa shuga 2, n'agbanyeghị nchịkwa glycemic, profaịlụ ọgwụ 40, 43. A na-ekpebikwa mmekọrịta ahụ. NAFLD yana ịbawanye n'ihe egwu ọrịa shuga na-arịa. N’aka nke ozo, ọnụnọ nke ọrịa shuga so ya na mmụba nke mbufụt, na-ebido oganihu nke NAFLD n'ime steatohepatitis (NaSg).

Ekwuputara na mgbe mkpokọta abụba dị na hepatocytes na -akpali mkpụrụ ndụ n'ihi ịba ụba nke abụba n'efu na imeju, a na-emejupụta imeju, a na-emepụta mkpụrụ ehi na - eme ka nnukwu mmeghachi omume na - eme ka ọ bụrụ ihe na - adịghị ike, nke na - ebute mbibi nke mkpụrụ ndụ imeju, ịmepụta steatohepatitis na - adịghị aholicụ mmanya,. 43. Mmekorita nke NAFLD na oke ibu visceral, na - ebute mmepe nke IR na ndi ozo

nsogbu nke metabolic na-esite na visceral adipose anụ ahụ nke nnukwu mkpụrụ ndụ na-arụ ọrụ na-arụ ọrụ (pro-mkpali cytokines - tumor necrosis factor-a (TNF-a), interleukin-6, wdg) adipocytokines - adipe-nectin, ghrelin, wdg. ), nke na-ekpebi mmepe nke metabolic syndrome na akụkụ nke ya, na-ekpebi ụzọ mgbochi na usoro ọgwụgwọ.

Tinyere aro maka iwetulata ahụ, mmega ahụ, imezu na idobe normoglycemia, na-eji usoro ọgwụgwọ belata, na vitamin, egosipụtago na ịdị mma nke PF. Nke a bụ n'ihi nkwenye ọrụ nke cytokines pro-inflammatory, gụnyere TNF-a, na pathogenesis nke NAFLD. N'ime ndị ọrịa nwere NASH, achọpụtara oke njupụta nke TNF-a mRNA ọ bụghị naanị na anụ anụ adipose, kamakwa na hepatocytes, nke gosipụtara site n'ọtụtụ plasma nke TNF-a, na-eduga n'ọzụ nke ọtụtụ nsogbu metụtara NAFLD 41, 46. Eziokwu ndị dị n'elu na-ekpebi ndụmọdụ nke gụnyere usoro ọgwụgwọ ọgwụgwọ NASH nke TNF-a na-egbochi ya. Enwere ike iji PF na ndị na-anabata ihe nnabata angiotensin (losartan) maka ebumnuche a.

Nnyocha na nyocha ụlọ ọgwụ gosipụtara ike nke PF igbochi mmepụta nke TNF-a site na ntinye mkpụrụ ndụ. N'oge na-adịbeghị anya, e bipụtara meta-analysis nke ọmụmụ ise (ndị ọrịa 147) nke na-enyocha ịdị irè nke pentoxifylline maka NAFLD, na-egosi mbelata ọrụ enzyme, interleukin-6, mmelite na akụkọ ihe mere eme - mbelata ọnụego steatohepatitis, mmụba na ngosipụta nke mbufụt lobular, mmezi nke nsogbu nke steatosis, usoro na ogo nke fibrosis. Usoro ọgwụ PF a tụrụ aro ka ejiri mee ihe n'ọmụmụ ihe ndị dị n'elu bụ 1200-1600 mg kwa ụbọchị maka ọnwa 6-12.

Mgbanwe ndị ziri ezi gosipụtara na-enye nkwado maka ntinye nke PF na ọgwụgwọ nke NAFLD. Nsonaazụ a tọrọ ntọala maka eziokwu ahụ bụ na na 2012 World Gastroenterological Organisation gụnyere pentoxifylline na ọgwụ akwadoro maka ọgwụgwọ nke NAFLD.

Obi ada mba. N'ime ihe ndị kachasị akpata mmepe nke ọrịa obi na-adịghị ala ala, ọrịa shuga na-ebute ụzọ yana ọrịa na-adịghị ala ala

Ọrịa pulmonary na-egbochi obara, ọbara mgbali elu, na ọrịa obi. Ohere dịnụ na ọnwụ nke ọrịa obi bụ 2.8 – 13.3 dị elu karịa ndị mmadụ na - arịa ọrịa shuga - nke a bụ ihe na - eche oke. Ihe kpatara ya bu osooso nke atherosclerosis, mmanu mbufụt, na mmebi obi akpukpo aru, nke anakpo “akuko obi n’aria,” nke n’agba mmalite nke nsogbu glucose metabolism nwere ike ibute systolic na, karie mgbe, oru diastolic nke ogha aka ekpe.

Isi mmetụta nke PF nwere ike ịba uru na mgbakasị obi, na mmepe nke a na-atụ anya ka ndị ogbugbo nke mmeju na-esonye, ​​ruo n'ókè dị ukwuu ha nwere ike ịbụ n'ihi mmetụta nke ọgwụ na mmepụta nke TNF-a na cytokines ndị ọzọ. A kọwo ọkwa dị ala nke cytokines na ngosipụta nke nkụda obi n'ọtụtụ nyocha na nyocha ụlọ ọgwụ. Nyochaa meta nke ọmụmụ isii na nyocha ntụle nke mmetụta PF (1200 mg kwa ụbọchị maka ọnwa 6) na ngosipụta nke nkụda obi gụnyere data ndị ọrịa 221 nwere mmerụ ọbara adịghị ike ịchọta ihe ịchọrọ? Gbalịa ọrụ nhọrọ akwụkwọ.

6. Collins R, Armitage J., Parish S. et al. // Lancet. -2003. - mpịakọta 361 (9374). - P.2005-2016.

7. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. // Lancet. - 2004 .-- Vol.364 (9435). - P.685-696.

8. De Sanctis MT, Cesarone M.R., Belcaro G. et al. // Angiology. - 2002 .-- mpịakọta 53, ngwaa 1. - P.S35-38.

9. Du J,, Ma W, Yu C.H., Li YM. // .wa. J. Gastroenterol. - 2014 .-- Vol.20 (2). - P.569-577.

10. Ferrari E, Fioravanti M, Patti AL. et al. // Pharmatherapeutica. - 1987. - Nkeji 5. - P.26-39.

11. Frampton J.E., Brogden R.N. // Ọgwụ Ọjọọ. -1995. - mpịakọta 7 (6). - P.480-503.

12. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra J.R. et al. // Clin. Nefrol. - 1995. — Nkeji 43. - P.116-112.

13. Incandela L, Cesarone M.R., Belcaro G. et al. // Angiology. - 2002 .-- Vol 53, suppl. 1.- P.S.31-34.

14. Keech AC, Mttchell P., Summanen P.A. et al. // Lancet. - 2007 .-- Vol.370 (9600). - P.1687-1697.

15. Lee Y., Robinson M, Wong N. et al. // J. Ọrịa shuga. - 1997 .-- mpịakọta 11 (5). - P.274-278.

16. Lopes de Jesus C.C., Ataiiah A.N., Valente O, Trevisani V.F. // www.thecochranelibrary.com

17. Matti R, AgiawalN, Dash D, Pandey B. // Vascul. Pharmacol - 2007 .-- mpịakọta 47 (2-3). - P.118-124.

18. McCormick B, Sydor A, Akbari A. et al. // Am. J. Akụrụ. Nke. - 2008 .-- Vol.52 (3). - P.454-463.

19. Mora C, Garcia J, Navarro J. // N. Engl. J. Med. -2000. - Oke 342. - P.441-442.

20. Moriwaki Y, Yamamoto T., Shibutani Y. et al. // abolmepe metabolism. - 2003 .-- Vol.52 (5). - P.605-608.

21. Navarro J.F., Mora C, Muros M, Garcia J. // J. Am. Soc. Nefrol. - 2005 .-- Vol.16 (7). - P.2119-2126.

22. Navarro J. F, Mora C, Rivero A. et al. // Am. J. Akụrụ. Nke. - 1999. - Mpịakọta 33. - P. 458-463.

23. Navarro J. F, Mora C, Muros M. et al. // Akụrụ Dis. - 2003 .-- Vol 42 (2). - P.264-270.

24. Navarro-Gonzalez J.F., Muros M, Mora-Fernandez C. // J. Complications. - 2011 .-- Vol 25 (5). - P. 314-319.

25. Parnetti L,, Ciuffetti G, Mercuri M. et al. // Pharmatherapeutica. - 1986. - mpịakọta 4 (10). - P.617-627.

26. Pasegawa G., Nakano K., Sawada M. et al. // Akụrụ Int. - 1991 .-- Vol 40. - P.1007-1012.

27. Rendell M, Bamisedun O. // Angiology. - 1992.-Vol 43 (10). - P.843-851.

28. Rooke TW., Hrsch AT., Misra S. et al. // Katheter. Cardiovasc. Interv. - 2012 .-- Vol. 79 (4). - P.501-531.

29. Roman G. // Ọgwụ taa (Barc). -2000. - mpịakọta 36 (9). - P.641-653.

30. Sakurai M, Komine I., Goto M. // Jap. Pharmacol Ọgwụ. - 1985. - Vol.13. - P.5-138.

31. Salhiyyah K, Senanayake E, Abdel-Hadi M. et al. Cochrane data Syst. Mkpu. / Pentoxifylline maka ịkọwapụta oge. - 2012. Jan 18, 1: CD005262. doi: 10.1002 / 14651858.CD005262.pub2.

32. Schandene L, Vandenbussche P., Crusiaux A. et al. // Immunology. - 1992. - Nkeji 76. - P.30-34.

33. Sebag J., Tang M., Brown S. et al. // Angiology. -1994. - mpịakọta 45 (6). - P.429-433.

34. Sever P.S., Poutter N.R., DahlöfB. et al. // Nlekọta Ọrịa shuga. - 2005 .-- Vol 28 (5). - P.1151-1157.

35. Sha MC, Callahan C.M. // Alzheimer Dis. Assoc. Nkewa - 2003 .-- Vol.17 (1). - P.46-54.

36. Shaw S, Shah M, Williams S, Fildes J. // Eur. J. Obi. Odighi. - 2009 .-- Vol.11 (2). - P.113-118.

37. Solerte S.B., Adamo S, Viola C. et al. // Ric. Clin. Lablọ nyocha. - 1985 .-- Vol.15, suppl 1. - P.515-526.

38. Solerte S.B., FioravantiM, BozzettiA. et al. // Acta Diabetol. Lat. - 1986. - Vol 23 (2). - P.171-177.

39. Stretter R.M., Remick D.G., Ward P.A. et al. // Biochem. Biophys. Res. Com. - 1988 .-- Vol 155. -P.1230-1236.

40. Tangher G, Bertolini L, Padovani R. et al. // Ọrịa shuga. - 2011 .-- Vol 53 (4). - P.713-718.

41. Tiniakos D.G., Vos M.B., Brunt E.M. // Ann. Mkpu. Pathol. - 2010 .-- Vol.5. - P.145-171.

42. Ndị otu ọmụmụ nyocha nke ACCORD na ìgwè nyocha anya. Mmetụta ọgwụgwọ ọrịa na-enwe banyere ọrịa retinopathy na ụdị ọrịa shuga 2 // N. Engl. J. Med. - 2010 .-- Vol.363. - P.233-244.

43. Van der Poorten D, Milner K. L., Hui J. et al. // Hepatology. - 2009 .-- mpịakọta 49 (6). - P. 1926-1934.

44. Viswahathan V, Kadrri M, Medimpukli S, Kumpatla S. // Int. J. Diab. Zụlite. Mba. 2010. - mpịakọta 30 (4). - P.208-212.

Oge Nzukọ Ọmụmụ Ihe Ntanetị Ndị Russia niile

Ihe omuma na ihe ngosi a gosiputara na saiti a, ihe nlere, ihe omuma banyere nyocha na okike, ebughi ndi okacha mara ahuike, adighi ele ya aka ma obu na akwalite ngwaahịa na ahia ma obu ihe ejighi ya nye onye oria a maka iji ogwu na uzo ọgwụgwọ. na enweghị dọkịta gị.

Ogwu, ihe omuma banyere nke di na saiti a, nwere contraindications, tupu i jiri ha, I gha aguta ntuziaka ma ghari onye okacha mara.

Echiche nke Gọọmentị nwere ike ọ gaghị adaba na echiche nke ndị ode akwụkwọ na ndị nkuzi. Nlekọta ahụ anaghị enye nkwa ọ bụla dabere na saịtị ahụ na ọdịnaya ya, gụnyere, na-enweghị nkwụchi, na-akwanye uru sayensị, mkpa, eziokwu, izu oke, ntụkwasị obi nke data sayensi nke ndị nkuzi nyere ma ọ bụ nrube isi nke ihe ahụ na ụkpụrụ mba niile nke ezigbo ahụike na / ma ọ bụ ọgwụ dabere. n'ihe akaebe. Saịtị a enweghị ọrụ ọ bụla maka aro ma ọ bụ echiche ọ bụla enwere ike ịnwe, ma ọ bụ maka itinye n'ọrụ nke ihe saịtị ahụ na-akọwa ọnọdụ dị iche iche. A na-enye ozi niile nke sayensi n'ụdị mbụ ya, na-enweghị mmesi obi ike zuru oke ma ọ bụ n'oge kwesịrị ekwesị. Nlekọta ahụ na-eme mgbalị nile iji nye ndị ọrụ ezi ozi ziri ezi ma nwee ntụkwasị obi, mana n'otu oge ahụ anaghị ewepụ ohere nke njehie.

Weputara udi ya na ihe mebere ya

A na-eme ọgwụ ahụ n'ụdị mbadamba, dragees na ihe ngwọta zubere maka infusions intravenous (droppers), injections and አስተዳደር intramuscular.

N'agbanyeghị ụdị ntọhapụ, ọgwụ ahụ bụchaghị isi ihe eji arụ ọrụ - pentoxifylline umi ahụ (na Latin - Pentoxyphyllinum).

N'okwu a, usoro onodu ogwu nke nọ n'ọrụ nwere ike di iche.

Mbadamba osisi a na-etinye n'ime ya nwere ọgwụ pentoxifylline 100 mg.

Ọgwụ a bụ otu nke vasodilators (vasodilators).

Ngwọta a na-eji egbu egbu nwere milimita iri abụọ nke ihe na-arụ ọrụ n'ime 1 ml. A na-ere ọgwụ ahụ na ampoules nke 1, 2, 5 ml.

Dragees (retard) bụ capsules nke nwere akpụkpọ ihe nkiri pink. Na mbadamba 1 nwere 400 mg nke ihe arụ ọrụ.

Usoro nke ime ihe

Ọgwụ a bụ otu nke vasodilators (vasodilators).

Mmetụta ọgwụ dị na ọgwụ na ebumnuche na nhazi nke mgbasa ọbara yana melite akụrụngwa ọbara.

Ọgwụ a nwere mmetụta ndị a n'ahụ ahụ onye ọrịa:

• na-ebelata viscosity ọbara, na-ebelata ohere nke ọbara ọgbụgba,
• dilates arịa ọbara (na-adịghị ala ala), na-ewepụ nsogbu na microcirculation ọbara,
• na - akwalite ọdụdụ oxygen anụ ahụ, na - egbochi mmepe nke hypoxia (n'ihi mgbasa nke arịa na akwara mmiri).
• enwekwu ụda diaphragm, akwara umeji,
• utịp bara uru na sistemụ ụjọ,
• Ọ na - enyere aka iwepụ ihe mgbu na mgbu n'ime akwara nwa ehi ndị metụtara nsogbu ọbara na aka.

Ọgwụ na-ebelata viscosity ọbara, na -echeta ohere nke ọbara ọgbụgba.

Ihe na-enyere aka

A na-eji ọgwụ ahụ na ọgwụgwọ nke ọrịa ndị a:

• imebi ọbara ọgbụgba aka na aka na aka (ọrịa Raynaud),
• mmebi anụ ahụ n'ihi microcirculation ọbara na-arịa ya na akwara na akwara (ọnya akpụkpọ trophlebotic, ọrịa postphlebotic, gangrene),
• nkwarụ ahụrụ anya na ntị nke metụtara ọbara okpu,
• Ischemia ụbụrụ,
• Ọrịa Buerger (thromboangiitis obliterans),
• Enweghi ike nke sitere na akwara ọmụmụ,
• n'ụbụrụ atherosclerosis,
• ọbara mgbali ike
• ọrịa angellathy na ndị ọrịa na-arịa ọrịa shuga mellitus,
• akwara obi
• ahịhịa dystonia,
• encephalopathy nke etiologies di iche iche.

A na-eji ọgwụ ahụ agwọ ọrịa nke ọrịa Raynaud's syndrome.
Ọgwụ dị mma maka ischemia n'ụbụrụ.
A na-eji Pentoxifylline mee ihe maka ike ọgwụgwụ nke ọkọnọ ọbara ezughi oke n'ahụ akụkụ akụkụ ọmụmụ ahụ.
A na-eji ngwá ọrụ ahụ agwọ ọbara mgbali elu.
A na-eji Pentoxifylline na ọgwụgwọ ọgwụgwọ angiopathy na ndị ọrịa nwere ọrịa mellitus.
Edere Pentoxifylline maka dystonia ahịhịa.

A na-ejikwa ngwá ọrụ ahụ na ọgwụgwọ nke osteochondrosis dị ka vasodilator inyeaka.

Ihe ngbanwe

Ndepụta nke contraindications maka iji ọgwụ ahụ gụnyere:

• Ọrịa porphyrin
• nnukwu myocardial infarction,
• ọbara ọgbụgba,
• nnukwu ọbara ọgbụgba.

Ejirighị ihe ngwọta a maka atherosclerosis nke akwara ụbụrụ na obi na nnukwu hypotension.

A na - ewepu ojiji nke Pentoxifylline na ndị ọrịa nwere hypersensitivity na mpaghara ahụ na - arụ ọrụ nke ọgwụ ahụ, ndị ọkachamara gụnyere na mejupụtara ya, ma ọ bụ ọgwụ ndị ọzọ sitere na otu xanthine.

Site na atherosclerosis nke akwara ụbụrụ na obi, ha anaghị a theụ ọgwụ n'ụzọ ọ bụla.

Etu ị ga-esi

Ọgwụ, dị n'ụdị dragees na mbadamba, bu n'uche maka nchịkwa ọnụ. Ọ dị mkpa ị takeụ ọgwụ mgbe ị risịrị nri. Can nweghị ike ịta ata. A ga-eji obere mmiri wee hichaa ha.

Dọkịta na-ekpebi kpọmkwem usoro ọgwụ ahụ n'otu n'otu maka onye ọrịa ọ bụla, na-eburu n'uche njirimara nke ahụ ya na-adabere na data sitere na onyonyo onyonyo nke ọrịa ahụ. Usoro usoro onunu ogwu bu 600 mg kwa ubochi (200 mg ugboro ato kwa ubochi). Mgbe izu 1-2 gachara, mgbe akara ngosipụta nke nsogbu ahụ na-akawanye njọ, a na-ebelata ọgwụ kwa ụbọchị ka 300 mg (100 mg ugboro atọ n'ụbọchị). Ejila ego ole a tụrụ aro maka ọgwụ kwa ụbọchị (1200 mg).

Ogologo oge ọgwụgwọ na pentoxifylline na mbadamba nkume bụ izu 4-12.

Enwere ike ịhazi ihe ngwọta ahụ intramuscularly, intravenously na intraarterially. A na-ekpebi usoro onunu ogwu n’otu n’otu, na-eburu n’uche nsogbu ọgbụgba na vaskụla. Ntuziaka maka iji ọgwụ ahụ na-ekwu na ịkwesịrị iji ngwọta dị ka ndị a:

1. Na ụdị nke ụmụ irighiri mmiri - 0.1 g nke ọgwụ a gwakọtara na salma 250-500 ml ma ọ bụ 5% gluuze gluu. Ọ dị mkpa iwebata ọgwụ ahụ nwayọ, n'ime awa 1.5-3.
2. Injections (intravenous) - na usoro ọgwụgwọ mbụ, a na-atụ aro 0.1 g nke ọgwụ (dilọm na 20-50 ml nke sodium chloride), mgbe ahụ, a na-abawanye dose ahụ ruo 0.2-0.3 g (agwakọta na 30-50 ml nke ihe mgbaze). Ọ dị mkpa iji nwayọ banye ọgwụ (0,1 g n'ime nkeji 10).
3. N'ime intramuscularly, a na-enye ọgwụ ahụ na usoro nke usoro 200-300 mg 2-3 ugboro n'ụbọchị.

Usoro usoro onunu ogwu bu 600 mg kwa ubochi (200 mg ugboro ato kwa ubochi).

Enwere ike ijikọ ihe ngwọta ya na nchịkwa ọnụ nke ụdị mbadamba ọgwụ ahụ.

Na-arịa ọrịa shuga

A na-akwado nkwadebe Pentoxifylline maka iji gwọọ ọnya trophic, gangrene, angiopathy yana ndiiche na usoro nlegharị anya na ndị ọrịa nwere ọrịa shuga. Agbanyeghị, ị ga-a takeụ ọgwụ ahụ naanị dịka dọkịta depụtara, onye na-edobe usoro onyonyo n’otu n’otu ma jide n’aka na ọ ga-agbanwe ya ma ọ bụrụ na onye ọrịa ahụ ewere ọgwụ hypoglycemic. -Medicationụ ọgwụ mgbochi onwe ya na pentoxifylline n'ọnọdụ a bụ ihe anabataghị, n'ihi na usoro ọgwụgwọ ahọpụtara n'ụzọ na-ezighi ezi nwere ike iduga mmepe nke mmeghachi omume na-adịghị mma (gụnyere hypoglycemic coma).

Pentoxifylline dị n’ịrụ ahụ

Ojiji Pentoxifylline nwere ike ịba uru ọ bụghị naanị na ọgwụgwọ nke ọrịa pathologies, kamakwa na egwuregwu, n'ihi na ọgwụ nwere ike ịbawanye ịdị irè nke ọzụzụ, nwekwuo ntachi obi, ma mee ka arụpụta nke nsonaazụ a chọrọ pụta n'ihi mmetụta bara uru n'ahụ.

Pentoxifylline nwere ike iwelie ịdị irè nke ọzụzụ, ịbawanye ntachi obi, mee ka mmezu nke ihe a chọrọ pụta dị ngwa.

A dụrụ ndị na-eme egwuregwu na ndị na-ahụ maka ahụ ume ka ha thisụọ ọgwụ a dị ka ndị a:

1. Ọ dị mkpa ịmalite site na obere usoro onyunyo - 200 mg 2 ugboro n'ụbọchị. Na-a pụ ọgwụ mgbe nri gasịrị.
2. Ọ bụrụ na enweghị nsonaazụ yana nnabata ọgwụ a zuru oke, ị nwere ike iwelie onunu ogwu ubochi rue 1200 mg (400 mg ugboro atọ kwa ụbọchị).
3. Iji rụpụta nsonaazụ kacha mma, a na-atụ aro ka ọ theụọ ọgwụ ahụ nkeji 30 tupu mgbatị ahụ yana awa ole na ole mgbe ọ gwụchara.
4. Oge ọ ga-eji ọgwụ ahụ bụ izu 3-4. Mgbe usoro ahụ gachara, ịkwesịrị ịhapụ izu maka ọnwa 2-3.

Ọkpụkpụ afọ

Ọgwụ nwere ike ibute ọnya imeju, ya na ihe isi ike na ntiwapụ nke ọrịa ọnya, na-akawanye njọ nke ọnya afọ, na-akawanye motility eriri afọ, na-ebelata agụụ, yana mmetụta nke nkụ na ọnya oke. N'ọnọdụ ndị a na-adịghị ahụkebe, a na-achọpụta ọbara ọgbụgba n'ime eriri afọ.

Ngwá ọrụ nwere ike ime ka mbufụt nke imeju, tinyere ike na outflow nke bile pụta.

Sistemụ akwara Central

Mgbu afọ, isi ọwụwa, ọgbụgbọ, na ụra na-adịghị mma nwere ike ịda.

Onye ọrịa na-a theụ ọgwụ ahụ na-ewekarị iwe ma nwee oke nchegbu.

Mgbe ị na-a theụ ọgwụ, mmeghachi omume nfụkasị anụ ahụ (itching, urticaria) na ujo anapulactic ga-ekwe omume.

Mmeghachi omume ndị ọzọ

Enwere ike ịbelata na ọnọdụ nke ntutu, mbọ, ọzịza, ọbara ọbara nke anụahụ (ịkwafu ọbara n'ihu na obi).

Mgbe ị na-a theụ ọgwụ, mmeghachi omume nfụkasị anụ ahụ na ujo anafilactic nwere ike ịmalite.

A naghị agụpụ ihe ndị na-ahụ ụzọ nke anya na mmepe nke anya nke anya.

Ntụziaka pụrụ iche

A na-eji ọgwụgwọ Pentoxifylline mee nke ọma na ndị mmadụ na-arịa ọnya afọ nke afọ na duodenum, ọrịa akụrụ na umeji, obi na -ewekarị ọbara ọgbụgba. Maka ụdị ndị ọrịa a, ndozi usoro mmado chọrọ ya na njikwa ahụike siri ike n'oge usoro ọgwụgwọ dị mkpa.

Mmanya ndakọrịta

Ndị dọkịta kwusiri ike na ndị ọrịa na-a aụ ọgwụ dabere na Pentoxifylline ewezuga mmanya mmanya tupu njedebe nke ọgwụgwọ.

A na-atụ aro ịhapụ ị alcoholụ mmanya tupu njedebe nke ọgwụgwọ na Pentoxifylline.

Mmanya Ethyl na-enwe ike ike agị agịkọta ọnụ n’ime ọgwụ ọgwụ, wepụ ha ma ọ bụ mee ka ihe ndị mejupụtara arụ ọrụ sie ike, nke nwere ike ibute mbelata ịdị mma nke ọgwụ ma ọ bụ kpatara nsogbu.

Mmetụta ikike ịchịkwa usoro

Ọgwụ ahụ emetụtaghị ikike ịchịkwa usoro mgbagwoju anya, gụnyere ụgbọ ala, ọ bụrụ na ụfọdụ nsonaazụ (ọgbụgbọ, ọgba aghara ụra, wdg), ntinye uche onye ọrịa nwere ike ịka njọ. Nke a nwere ike belata ogo ịkwọ ụgbọala na ụgbọ ala ndị ọzọ.

Ihe enyere ndi umuaka aka

A mụọbeghị ịdị irè na nchekwa nke ọgwụ n'oge ọ bụ nwata, yabụ, ndị na-emepụta Pentoxifylline anaghị akwado ịkọwa ọgwụ a nye ndị ọrịa na-erubeghị afọ 18.

A naghị atụ aro Pentoxifylline iji nye ndị ọrịa na-erubeghị afọ 18 ọgwụ a.

Agbanyeghị, na omume, ọ bụrụ na ọ dị oke mkpa, ndị dọkịta nwere ike ịkọtara ụmụaka ọgwụ a ka ụmụaka karịa afọ 12. Ọtụtụ mgbe nke a bụ n'ihi nsogbu mgbasa ọbara na adịghị ike nke iji usoro ọgwụgwọ ọzọ.

Dodoụbiga ya ókè

Site n'iji ọgwụ ị highụ ọgwụ ọ highụedụ ogologo oge, ihe mgbaàmà ndị a nke ịdoụbiga mmanya ókè nwere ike ime:

• ọgbụgbọ, vomiting nke "kọfị ahịhịa" (na-egosi mmepe nke ọbara ọgbụgba),
• anya ntughari
• adịghị ike
• ogwe.

N'okwu ndị dị oke njọ nke ịdoụbiga mmanya ókè, nkụda mmụọ, ịda mbà nke akụkụ iku ume, anaphylaxis.

N'ọnọdụ ndị ka njọ, a na-ahụ nkụda mmụọ, nkụda mmụọ iku ume, anaphylaxis.

Mmekọrịta na ọgwụ ndị ọzọ

Ọgwụ nwere ike ịkwalite nsonaazụ ọgwụ ndị a:

• anticoagulants
• thrombolytics
• ọbara mgbali belata ọgwụ
• ọgwụ nje
• insulin nwere ya na ọgwụ hypoglycemic,
• nhazi nke valvik acid.

Ojiji nke Pentoxifylline na ọgwụ ndị nwere cimetidine na-ebulite ohere nke nsonaazụ ndị ọzọ. Nkwadebe dabere na ketorolac na Mexico adabaghị na Pentoxifylline, n'ihi na mgbe gị na ọgwụ na-emekọrịta ihe, ha na-amụba ohere nke ịmalite ịmịnye ọbara n'ime.

Nwere ike ịzụta ngwaahịa ahụ naanị ma ọ bụrụ na ịnwere ọgwụ ziri ezi dọkịta gị nyere gị.

A naghị atụ aro ka ikpokọta ojiji nke ọgwụ a na ojiji nke xanthines ndị ọzọ, ebe ọ bụ na nke a nwere ike ibute oké ụjọ ụjọ.

Na usoro ọgwụgwọ nke ọrịa ọrịa na - akpata nsogbu, ana - eji ihe ana - echu Pentoxifylline:

• Cavinton
• Trental
• Pentoxifylline-NAS,
• Piracetam
• Pentilin
• Brọda
• Fluxital
• Latren
• nicotinic acid.

Iji chọpụta nke ọgwụ ndị kachasị mma maka otu ọrịa mgbasa, ị kwesịrị ịkpọtụrụ dọkịta gị.

EGO NA-EGO AKUKO EGO. Ọ dị m mkpa iji ọgwụ ọjọọ wee dechie arịa ọbara. Pentoxifylline

Nyocha Pentoxifylline

Imirikiti ndị dọkịta na ndị ọrịa na-emeghachi omume n'ụzọ dị mma maka ojiji Pentoxifylline.

E. G. Polyakov, neurosurgeon, Krasnoyarsk

Ọgwụ nwere mmetụta dị mma n'ọrịa dịgasị iche iche nke mgbasa nke etiti na akwara. Ngwá ọrụ dị mma ma dị ọnụ ala, ya mere ọ bịara dịrị maka ụdị ndị ọrịa dị. Ọdịmma ọghọm nke ọgwụ ahụ gụnyere mmetụta adịghị ike na angiopathies.

Lily, onye gbara afọ 31, bụ Astrakhan

M na-arịa ahụhụ site na mwakpo nke dystonia ahịhịa, nke metụtara ndụ m nke ukwuu. Ugbu a, a na-emeso m Pentoxifylline. Site na mwakpo ọzọ, amalitere m iji ọgwụgwọ a na usoro (n'ime ụbọchị 10). Enyemaka na-apụta n’ụbọchị mbụ ọgwụgwọ, mgbe ụbọchị iri gachara, mgbaama niile na-apụ kpamkpam. Ekwesịrị itinye uche pụrụ iche na ọnụ ahịa ọgwụ ahụ: ọ dị ala nke na mbụ ọ na-adị egwu. Mana ogo Russian Pentoxifylline adịghị njọ karịa nke analogues nke mba ọzọ, nke na-eri 2, ma ọ bụ karịa ugboro atọ karịa ọnụ.

Igor, onye gbara afọ 29, Volgograd

Iji mee ka microcirculation ọbara dị na akụrụ, a ga-ewere vasodilators. Edere Curantil na mbụ, mana isi ya wutere ya nke ukwuu, yabụ na m ga-agbanye na Trental. Ndị a bụ ọgwụ ọgwụ dị mma, mana dịkwa oke ọnụ, yabụ m kpebiri iji Pentoxifylline nke Rọshịa dochie ha. Ahụghị m ọdịiche ọ bụla (belụsọ maka ọnụahịa). Ha na-emekwa ihe, ha anaghị ebute mmeghachi omume ọjọọ, ha na-arụ ọrụ ha zuru oke.

Ngwakọta na ụdị ntọhapụ

Mbadamba 100 na 400 mg, nke nwere mkpuchi pink. Ihe ngwugwu nwere ngwongwo 20 na 60.

Mkpụrụ mbadamba 100 na 400. Ihe ngwugwu nwere ngwongwo 20 na 60.

Ejiri mbadamba mkpụrụ osisi 400 na 600 mg nke nwere akara eji etinye aka - ngwugwu ahụ nwere iberibe iri ise.

Ampoule nwere usoro iji gwọọ ya. Na 1 ml nke ihe ngwọta nwere:

• pentoxifylline - 20 mg,
• sodium chloride - 90 mg,
• mmiri - ruo 1 ml.

Dị na ampoules nke 5 ml. Ihe ngwugwu nwere ampoules 5.

Ọ dị ize ndụ iji pentoxifylline n'oge afọ ime?

A maara na a na-ahapụ ọgwụ ọ bụla ka ewere ya n’oge

Naanị ma ọ bụrụ na ọ gafere nchekwa nchekwa pụrụ iche maka nne na nwa ebu n’afọ. Pentoxifylline agafereghị ụdị nchịkwa ahụ, yabụ, ntuziaka niile na-egosi na ọ bụ nke ime n'afọ.

Enwere ihe ngosi maka ịkọwa pentoxifylline n'oge afọ ime?

Dị ka ị maara, n'ime izu ndị mbụ nke ịtụrụ ime, ọgwụ ọgwụ niile na - agha ọgwụ mgbochi. A ga-eji ọgwụ ndị a na-emebeghị maka nchekwa iji dozie izu izu iri abụọ nke afọ ime, ọ bụcha n'okpuru nlekọta nke dọkịta dị ime.

Mana enwere ike ịnwe ọnọdụ nwa ebu n’ịgba ahụ na ọ dị mkpa ị drugsụ ọgwụ ndị a. A na-eji ha eme ka ọbara na oxygen na -eme akwa Plasenta.

Mmetụta dị a doesaa ka ọgwụ ahụ nwere n'oge ime?

Pentoxifylline na - emetụta microcirculation na anụ ahụ, na - agbasawanye obere arịa ọbara, belata viscosity ọbara ma melite ọfụma na arịa ọbara. Ọbara na-ebugharị nke ọma, si otú a na-eme ka oxygen oxygen na Plasenta. Ihe omume ndị a dị ezigbo mkpa maka mmepe nke nwa ebu n’afọ.

Obi abụọ adịghị ya, ndị dọkịta tụlere uru na ọghọm dị iche iche banyere ịde ọgwụ ahụ n'oge ịtụrụ ime. Ngwongwo ya bara uru na-adịkarị elu karịa ihe ize ndụ nke mmetụta ọjọọ.

Nyocha nke ụmụ nwanyị dị ime na-ewere Pentoxifylline na-abụkarị nke dị mma.

Dabere na ntuziaka ahụ, edeghị Pentoxifylline n'oge afọ ime / lactation.

Ebe ọ bụ na enweghị ahụmịhe banyere iji ọgwụ ahụ eme ihe n'etiti ụmụ nwanyị dị ime, na egosighi nchekwa nke ọgwụ na mmepe nwa ebu n'afọ, edeghị mbadamba pentoxifylline maka ụmụ nwanyị na-achọ nwa.

Onweghi ike inye data na mmiri ara ara iji nyefee ya ọgwụ, yabụ, ọ bụrụ na ọ dị mkpa iji gwọọ ọrịa, nwanyị kwesịrị ikpebi ngwụcha ọmụmụ nwa ka ọ ghara ikpughe nwatakịrị ahụ.

Mkparịta ụka ọgwụ ọjọọ

Na-akwalite nsonaazụ antihypertensive na ọgwụ antidiabetic (a ga-belata dose ahụ). Mgbe ejikọtara ya na ndị nwere ọmịiko, ndị na-akpọ ganglioblocloc, vasodilators, iwetulata mgbali ọbara, enwere ketolorac, meloxicam - mmụba na oge prothrombin nwere nsogbu ọbara ọgbụgba, ya na heparin, ọgwụ fibrinolytic yana ọgwụ anticoagulant na - apụtakarị - ịba ụba anticoagulant.

Cimetidine na-abawanye itinye uche n'ihe

Pentoxifylline

n'ọbara nwere ike inwe mmetụta nke ọghọm ya.

Pentoxifylline, dịka iwu, na-akwalite nsonaazụ ọgwụ nke belata ọbara mgbali elu, yana ọgwụ ezubere maka ọgwụgwọ

Nchịkọta ojiji nke Pentoxifylline yana ụfọdụ ọgwụ / bekee nwere ike bute mmepe nke mmetụta ndị a:

• Cimetidine: na-eme ka ịbawanye ụba nke pentoxifylline dị na plasma ọbara, n'ihi nke a, ohere nke mmeghachi omume ọjọọ,
• Valproic acid, heparin, theophylline, ọgwụ fibrinolytic, antihypertensive na hypoglycemic jami (insulin, ọgwụ hypoglycemic waki), ọgwụ ndị na-emetụta usoro coagulation ọbara (anticoagulants, thrombolytics), ọgwụ mgbochi (gụnyere cephalosporins, na-abawanye):
• Xanthines ndị ọzọ: oke iwe ụjọ na-amalite.

Nyocha Ntinye

Cerebrovascular pathology, ọkachasị akụkụ akwara arteriosclerosis, ọnọdụ mgbe ọrịa myocardial infarction, diabetic nephroangiopathy na ọrịa shuga ndị ọzọ na-arịa ụkwara ume ọkụ (ọrịa Raynaud, endarteritis, wdg), nje vaskụla nke anya (ọrịa na ọbara ọgbụgba na-adịghị ala ala) na retina na.

Nrụrụ ọrụ ịnụ ntị nke vaskụla sitere.

Kenye ya n'ime intravenia na intraarterially. N'ime, were, malite na 0.2 g (mbadamba abụọ) ugboro atọ kwa ụbọchị mgbe nri gachara, n’erighị ata ata. Mgbe mmalite nke ọgwụgwọ ọgwụgwọ (na-abụkarị mgbe izu 1-2 gasịrị), a na-ebelata dose ahụ ka ọ dị 0.1 g (1 mbadamba) ugboro atọ n'ụbọchị. Usoro ọgwụgwọ bụ izu 2-3. na ndị ọzọ.

Ọ bụrụ na ọ dị mkpa (ịkpa oke nsogbu ma ọ bụ mgbasa ụbụrụ / ischemic strok /) ka a na-ahazi ya ma ọ bụ intraarterially. A na-edozi 0.1 g (1 ampoule) na intravenously na 250-500 ml nke ihe ngwọta sodium chloride isotonic ma ọ bụ na 5% glucose maka nkeji 90-180.

Enwere ike ịbawanye ọgwụ kwa ụbọchị ka ọ dị 0.2-0.3 g. N'ime ahụ ike, a na-ebu ụzọ 0.1 g nke ọgwụ mbụ na 20-50 ml nke ihe ngwọta sodium chloride isotonic, na ụbọchị ndị na-eso ya, 0.2-0.3 g nke ọ bụla (n'ime 30-50 ml nke ihe mgbaze). Tinye ọnụego 0.1 g (5 ml nke ọgwụ 2% nke ọgwụ) maka nkeji 10

Usoro usoro onunu ogwu na uzo ochichi: mbadamba, injections, dropper

A na-a drugụ ọgwụ ahụ ọnụ na parenterally, dabere ogo ọrịa ahụ.

Mgbe ejiri ya n ’ọnụ, a na-eji mbadamba ọgwụ nwere ọgwụ nke 100 mg. Ha na - ebido were karia 200 mg - mbadamba abali ato ugboro ato n’eri nri. Mgbe emesiri, a g’enwe ihe ogwugwo, a na-ebelata ogwu a, a ga na -ebe mbadamba ya ugboro ato n ’ubochi. Iji usoro mbadamba mbido eme ihe were otu ọnwa.

N'ime ọrịa siri ike na nke siri ike nke akwara dị n'ime, a na-enye pentoxifylline ọgwụ ampoules. Enwere ụzọ abụọ nke nchịkwa ọgwụ: intraarterial na intravenous.

A na-ahụ maka ihe eji ahụ eme ihe n'ụdị onye dropper. A na-eji otu ampoule kwa 250 ml nke sodium chloride solution, ma ọ bụ ngwọta glukoni. A na-elekọta ọgwụ a karịa otu awa na ọkara ruo awa abụọ, nwayọ.

Enwere ike ịbawanyewanye kwa ụbọchị site na ezigbo ndidi ruo 0.2-0.3 g (dabere na ngosipụta).

Intraarterially, ha na-amalite inye ọgwụ site na ọgwụ nke 0.1 g nke ọgwụ kwa 50 ml nke sodium chloride solution, mgbe ahụ - 0.2-0.3 g

A na-agbanye azịza ihe nwayọ nwayọ karịa nkeji iri. Usoro ahụ na-eji 10 infusus.

Na ọrịa vaskụla

A na-eji Pentoxifylline (Trental) mee ihe nke ọma na ọgwụgwọ nke dyscirculatory na-adịghị ala ala

Ọrịa Cerebrovaskụla bụ ihe kacha egbu ndị mmadụ, ọkachasị ndị agadi. Ọtụtụ mgbe, ọ bụghị naanị ọrịa na-arịa ọrịa ụbụrụ, kamakwa nke nke adịghị ala ala.

Na Russia, ihe ọghọm nke ụbụrụ na - adịghị ala ala bụ nke akpọrọ DE - discirculatory encephalopathies. A na-egosipụta ọrịa a na mmebi nke ọrụ ụbụrụ na-aga n'ihu, bụ nke ọdịda ọbara na-akpata.

Ihe mgbaàmà nke ọrịa a bụ ọrịa akwara ozi, nke mmetụta uche na nke ịmata ihe, mgbe enwere ncheta, mbelata nke ọrụ ọgụgụ isi, nsogbu ihi ụra na nsogbu ndị ọzọ.

Iji gwọọ ọrịa a, ndị dọkịta depụtara Pentoxifylline, ma ọ bụ analogues ya. Ọgwụ ndị a na - eme ka microcirculation dịkwuo mma, belata nchịkọta platelet, ma na - abawanye ọbara.

Dị ka ndị ọkà mmụta sayensị si kwuo, ojiji nke Pentoxifylline maka izu atọ ma ọ bụ anọ na-eme ka ọbara na-erugharị site na 17%. Agbanyeghị, iji ọgwụ eme ihe adịghị akpata ọrịa intracerebral ohi syndrome.

A na-eji Pentoxifylline mee ihe n'ọtụtụ ebe iji na-agwọ ọrịa vaskụla. Ndị a gụnyere ịkọwapụta ihe dị oke ọnụ na ndị ọrịa nwere mmebi nke arịa nke mpaghara ala. Ọgwụ dị irè n'ịgwọ ọrịa trophic ọnya nke ala ala.

N’egwọ ọnya trophic

Ọrịa a na-akpatara ndị ọrịa oke nhụjuanya -

gwọọ nwayọ nwayọ, nwee echiche ịlaghachi azụ.

Ojiji nke Pentoxifylline bụ ihe ziri ezi na ọgwụgwọ nke ọnya trophic. Ọgwụ ahụ, na-eme ka ọbara na-ebugharị na mpaghara emetụtara, na-akwalite ọgwụgwọ ngwa ngwa nke ntụpọ akpụkpọ ahụ megide ndabere nke ụzọ ndị ọzọ.

Na ọrịa imeju

Pentoxifylline na -ebelata ọnọdụ nke nsogbu

N'afọ ndị na-adịbeghị anya, a chọpụtala ebe ndị ọhụrụ na iji Pentoxifylline. Ka ọ dị ugbu a, e gosipụtawo mmetụta dị mma nke ịgwọ ya na ọgwụ a maka ọrịa dị ka ịba ọcha n'anya ịba ọcha n'anya.

Nyocha banyere iji Pentoxifylline na-abụkarị ezigbo mmadụ. Ọgwụ dị irè maka ọnya anụ ahụ nke ọtụtụ akụkụ na sistem. Emekarịrị onye na-arịa ọrịa vaskụla na-amanye ị medicinesụ ọgwụ ugboro abụọ n'afọ - naanị mgbe ahụ ị ga - ejikwa ọnọdụ gị na usoro ọrịa ahụ.

A na-egosiputa ọtụtụ nyocha banyere ojiji Pentoxifylline na ụmụ nwoke na-ata ahụhụ site na iwepu endarteritis na ihe ijuanya na-agbanwe agbanwe. Pentoxifylline bụ ọgwụ nke nọmba 1 ha, ebe ọrịa a na-aga n'ihu.

Kedu ihe bụ mbadamba na ihe ngwọta sitere? Edere ọgwụ ahụ maka nsogbu ọgbaghara n'ọbara, ọrịa trophism, ọrịa Raynaud, obliterating endarteritis, post-thrombotic syndrome, frostbite, gangrene, ọnya ụkwụ ukwu ala, varicose veins, ụbụrụ atherosclerosis, akwara neuroinfection, na dyscirculatory encephalopathy.

Ihe ozo gosiputara iji Pentoxifylline bu: myocardial infarction, akwara obi, oria akwara, oke nsogbu nke obara n’iru na retina, choroid, otosclerosis, enweghi ike nke vaskụla.

Pentoxifylline ngwọta, ntuziaka maka ojiji

A na-achịkwa ọgwụ dị na ampoules intramuscularly na intraarterially n'ọnọdụ supine onye ọrịa.

Site na usoro pathology nke sisitem akwara, a na-agbada usoro ahụ ka ọ bụrụ pasent 50-70 nke ọkọlọtọ.

Ejiri nwayọ nwayọ rụọ ọrụ, gbakọọ dịka atụmatụ ahụ si dị: 50 mg maka 10 ml nke sodium chloride 0.9%, gbanyere nkeji iri, wee gbanye na mpekere: 100 mg dilted na 250-500 ml nke sodium chloride 0.9% ma ọ bụ dextrose solution 5 %

Intraarterially: 100 mg dilis na 20-50 ml nke sodium chloride.

N'ime intramuscularly nwere oke nlekọta nke ukwuu ugboro atọ n'ụbọchị, 100-200 mg.

Mbadamba pentoxifylline, ntuziaka maka ojiji

Na mgbakwunye na nchịkwa parenteral, ọ bụ ihe nwere ike ị insideụ ọgwụ ahụ mgbe nri ugboro abụọ n’ụbọchị, na 800-1200 mg. Usoro onunu ogwu ubochi mbu n’odide bu 600 mg, jiri nwayọ belata ego ọgwụ a rue 300mg kwa ụbọchị. A na-ewere ụdị ọgwụ dị ogologo oge ugboro abụọ n'ụbọchị.

Egosiputara Pentoxifylline angioprotector ka ejiri ya mee ihe n’ọgwụgwọ ọrịa nke ọrịa obi.

Edere ọgwụ maka ọgwụgwọ arịa arịa, yana enweghi oke ume.

Pentoxifylline, abanye n'ime ọbara, na-eme ihe na mpaghara na arịa ndị emetụtara, na-ewepụ nkwakọba atherosclerotic, na-ewusi mgbidi venous.

Ihe ngosi maka ogwu nke ogwu:

• mmebi nke mgbasa oke (endarteritis, angiopathy),
• atherosclerotic ma ọ bụ discirculatory angiopathies,
• ọghọm nke ụbụrụ,
• post-ischemic, ọnya na-arịa ọnya afọ.

Ngwọta maka infusion, ngwọta maka nchịkwa intravenery na intraarterial

Nlekọta intraarterial: ọnụego - 10 mg kwa nkeji, ọgwụ mbụ - 100 mg ọgwụ a (na 0.9% sodium chloride solution na olu nke 20-50 ml), n'ọdịniihu, a na-abawanye ọgwụ ahụ ruo 200-300 mg (na 0.9% sodium chloride solution. olu 30-50 ml).

Ejiri Pentoxifylline rụọ ọrụ nwayọ nwayọ nwayọ karịa 90-180 nkeji:

• Ngwọta maka infusion: dose - 50-100 mg, ma ọ bụrụ na ọ dị mkpa - 200 mg (karịa kwa ụbọchị - 300 mg). N'oge nchịkwa, onye ọrịa kwesịrị ịnọ n'ọnọdụ kachasị,
• Ngwọta maka nchịkwa intravenous na intra-art art: dose - 100 mg nke ọgwụ ahụ na 0.9% sodium chloride solution ma ọ bụ 5% glucose (dextrose) na mmiri nke 250-500 ml. Na nnukwu atherosclerosis nke arịa ụbụrụ, amachibido iwebata ọgwụ n'ime akwara carotid.

Ndị ọrịa nwere akụrụ gbasara akwara na-adịghị ala ala (iwepu ihe na-erughị 30 ml kwa nkeji) chọrọ mbelata nke 30-50%.

Maka ọgwụgwọ nke ọnya na-adịghị ala ala ma ọ bụ ọrịa mamịrị atherosclerotic, a na-enye infringvenous infusion ụbọchị niile ma ọ bụ ụbọchị niile.

Mpempe Pentoxifylline ka a na-ewere ọnụ site na-enweghị ita ata ma ọ bụ mebie (dum), were mmiri sachaa, ọkacha mma mgbe ị gachara.

Dịka iwu, etinyere mbadamba nkume nke Pentoxifylline na pcs abụọ. 3 ugboro n'ụbọchị. Ihe dịkarịa ala kwa ụbọchị bụ 600 mg, ihe kachasị bụ 1200 mg. Ọtụtụ mgbe, mgbe izu 1-2 gasịrị, a na-ebelata otu ọgwụ ka ọ bụrụ mbadamba 1, ebe ọtụtụ Pentoxifylline na-agbanwe agbanwe.

Dọkịta kpebiri oge ọgwụgwọ ọgwụgwọ n'otu n'otu, dịka iwu, ọ bụ ọnwa 1-3.

Na ọdịda akụrụngwa na-adịghị ala ala (mwepụ nke okike na-erughị 10 ml kwa nkeji), ịbelata mmiri ugboro abụọ dị mkpa.

Pentoxifylline n'ụdị usoro ọgwụgwọ ogologo oge ka a na-ejikarị oge nchịkwa ugboro abụọ kwa ụbọchị, oge usoro ọgwụgwọ ahụ sitere na izu 2-3 ma ọ bụ karịa.

• Ọrịa Angioneuropathy (paresthesia, ọrịa Raynaud),
• Ọrịa ọgbụgba na-arịa ọbara, nke a na-ebute site na usoro mkpali, ọrịa shuga mellitus, atherosclerosis,
• Ihe ọghọm Ischemic cerebrovascular (ajọ ọrịa na-adịghị ala ala),
• Ikpochapu endarteritis,
• Ọrịa na - adịghị ala ala, akwara ozi na ọdịda akwara akwara na retina ma ọ bụ choroid,
• Ọrịa anụ ahụ na-emetụta akụkụ ahụ ọria ma ọ bụ microcirculation akwara (frobite, trophic ọnya, gangrene, post-thrombophlebitis syndrome),
• Mmetụta ntị na-arịa etiology
• Encephalopathy nke atherosclerotic na etiology diskiculatory.

Ọ bụ dọkịta ga-ekpebi oge ọ ga-eji usoro ọgwụgwọ gwọọ ya na ụbọchị ọ bụla, ọ dabere na nchoputa ya, ogo akara ya na njiri mara ya.

A na-ewere mbadamba ahụ ozugbo nri, na-elo mmiri ozugbo, ọ bụghị izọpịa ma na-ata ata, na-a plentyụ nnukwu mmiri ma ọ bụ mmiri mmiri ọzọ.

Dịka ntuziaka ahụ si dị, a na-enye ndị ruru ihe karịrị afọ 18 ọgwụ ọgwụ ọgwụ 200 mg otu oge ugboro atọ n'ụbọchị. A na-enye mbadamba mg mg mg na ọgwụ 1 na-erughị ugboro 2 n'ụbọchị. Ogologo oge ọgwụgwọ dị ka ntuziaka ahụ si dị izu 3, ọ bụrụ na ọ dị mkpa, dọkịta na-agbatị ma ọ bụ na-eme ka oge ọgwụgwọ ahụ dị mkpụmkpụ.

Ọnụ ọnụahịa Pentoxifylline

Ọnụ ego ọgwụ ahụ na ihe ngosi ya na-adabere na onye nrụpụta, na usoro onodu ogwu na ụdị ntọhapụ. Ná nkezi, ọnụ ahịa ọgwụ ụlọ Pentoxifylline sitere na 33 ruo 72 rubles.

Ọnụ ego nke Trental sitere na 157 ruo 319 rubles, Agapurin na-efu site na 90 ruo 137 rubles.

Ọnụahịa Pentoxifylline dị na mbadamba 0.1 g sitere na 85 ruo 130 rubles kwa ngwungwu 60 iberibe.

Ọnụahịa Pentoxifylline 2% ampoules nke 5 ml bụ 40 rubles kwa 10.

Ọnụ ego dị nso na Pentoxifylline bụ: mbadamba azụ (400 mg nke ọ bụla, pọọg 20) - site na 273 rubles, mbadamba mkpụrụ osisi (100 mg, 60 PC.) - site na 62 rubles, ihe ntụtụ (20 mg / ml , Ampoules 10 nke 5 ml ọ bụla) - site na 35 rubles., Na-etinye uche maka nkwadebe nke ihe ngwọta maka nchịkwa intravenous na intra-artery (20 mg / ml, ampoules 10 nke 5 ml) - site na 36 rubles.

Ọnụ ego nke mbadamba Pentoxifylline dị na ọgwụ ọgwụ Moscow bụ 450-600 rubles, dabere na usoro onyonyo na ọnụ ọgụgụ nke mbadamba ihe dị na ngwugwu ahụ.